In a recently published article in Science,Zak et al.discovered that the Janus kinase(JAK)inhibitor ruxolitinib alters innate and adaptive immune cells to an unanticipated,predominantly immune-stimulatory phenotype in...In a recently published article in Science,Zak et al.discovered that the Janus kinase(JAK)inhibitor ruxolitinib alters innate and adaptive immune cells to an unanticipated,predominantly immune-stimulatory phenotype in mouse infection models.1 This finding motivated a clinical study,which showed that ruxolitinib treatment in combination with the anti-PD1 immune checkpoint inhibitor(ICI)nivolumab in a cohort of relapsed or refractory Hodgkin lymphoma(HL)patients demonstrated promising responses.展开更多
基金Own work on HL is funded by the Deutsche Forschungsgemeinschaft(SFB 1530,C01)Open access funding enabled and organized through project DEAL.
文摘In a recently published article in Science,Zak et al.discovered that the Janus kinase(JAK)inhibitor ruxolitinib alters innate and adaptive immune cells to an unanticipated,predominantly immune-stimulatory phenotype in mouse infection models.1 This finding motivated a clinical study,which showed that ruxolitinib treatment in combination with the anti-PD1 immune checkpoint inhibitor(ICI)nivolumab in a cohort of relapsed or refractory Hodgkin lymphoma(HL)patients demonstrated promising responses.
